Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Treatment of rats with spinal cord injury using human bone marrow-derived stromal cells prepared by negative selection

Romero-Ramírez L., Wu S., de Munter J., Wolters EC., Kramer BW., Mey J.

Prospective Study on Spinal Cord Injury, Neuroinflammation, published in J Biomed Sci (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Biomed Sci (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32066435
PMCID
PMC7026953
DOI
10.1186/s12929-020-00629-y
Citations
25

Abstract (original English)

Background Spinal cord injury (SCI) is a highly debilitating pathology without curative treatment. One of the most promising disease modifying strategies consists in the implantation of stem cells to reduce inflammation and promote neural regeneration. In the present study we tested a new human bone marrow-derived stromal cell preparation (bmSC) as a therapy of SCI. Methods Spinal cord contusion injury was induced in adult male rats at thoracic level T9/T10 using the Infinite Horizon impactor. One hour after lesion the animals were treated with a sub-occipital injection of human bmSC into the cisterna magna. No immune suppression was used. One dose of bmSC consisted, on average, of 2.3 million non-manipulated cells in 100 μL suspension, which was processed out of fresh human bone marrow from the iliac crest of healthy volunteers. Treatment efficacy was compared with intraperitoneal injections of methylprednisolone (MP) and saline. The recovery of motor functions was assessed during a surveillance period of nine weeks. Adverse events as well as general health, weight and urodynamic functions were monitored daily. After this time, the animals were perfused, and the spinal cord tissue was investigated histologically. Results Rats treated with bmSC did not reject the human implants and showed no sign of sickness behavior or neuropathic pain. Compared to MP treatment, animals displa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Mesenchymal Stem CellsHumansSpinal Cord InjuriesInflammationMesenchymal Stem Cell TransplantationInjections, IntraperitonealInjections, SpinalNerve Regeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research